Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
about
In vivo screening for anti-osteoporotic fraction from extract of herbal formula Xianlinggubao in ovariectomized miceBone Mineral Accrual Is Associated With Parathyroid Hormone and 1,25-Dihydroxyvitamin D Levels in Children and Adolescents.Dynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosisInterpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease.Chronic arthritis leads to disturbances in the bone collagen network.Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women.The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial.Characterization of Salvia miltiorrhiza ethanol extract as an anti-osteoporotic agent.Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.A hospital based study of biochemical markers of bone turnovers & bone mineral density in north Indian women.Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring."Fit-for-purpose" method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studiesDenosumab in osteoporosis and oncology.Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone.Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.Models and screening assays for drug discovery in osteoporosis.Biochemical markers of bone turnover - uses and limitations.A short account of metastatic bone disease.The Utility of Biomarkers in Osteoporosis Management.Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China.Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1.Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption.Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
P2860
Q28543533-9A7B718B-8E8F-4FD3-8C58-006FB707ACAEQ30278911-6374F52B-1A24-45F4-A5E8-2C92CD11739CQ30476071-A69E317E-3ED0-497A-AB76-EE0541AAF360Q33343829-5EB11BA2-1C43-4D8C-AABF-FC660B32CF8AQ33524546-C0AFA96C-9A52-4E87-905E-1A24514F8FAFQ33723041-52C2BE50-B3C6-4162-9997-DF51B635932BQ33819018-588BB10E-874D-40DE-A8D6-B0A83BBCBD1EQ34083935-DDE39A0F-6ED4-459A-9CD0-2E788C5A4088Q36792968-9AB4552C-B7FD-4832-A600-DC28BFFC9353Q36855629-79F9B38E-7F42-4D40-8C60-52E26B6471FCQ37176381-C62B3BFE-D7BA-49AD-B243-DADCFDD69D28Q37214552-AAB51E6E-4366-4CAD-9423-A05FC86895ECQ37557994-B9A91568-B309-499D-AF1B-C4E1FBF9E3DAQ37800179-FABDE96D-854C-4500-993C-31B86B961718Q37952851-8D4712A0-E85A-42B5-84C1-BF2CCDD47A8FQ38028513-F938A564-ED08-49B2-B898-C46A8BCA6F90Q38176560-48863D1C-8DD7-453D-AB44-1E91F707DA5FQ38255403-738A9DAE-18B6-47E2-9037-8629A01B1FCDQ38921875-E323BFBF-F6DF-4F1E-9F8C-E8C8F3F4B642Q39234438-EDC87027-D037-45AB-AA83-130347F29D72Q45155246-FC8FB14D-9A0E-47D4-BE74-E9C95F154F90Q46728028-C64FECFA-836F-422A-9FC8-00DB7455866CQ48853983-E8B827AB-5827-4F3A-B205-985B5F5DAEBDQ50902621-D7F5CDA4-3526-45CF-B189-D8E047151655Q51152617-1A3A0F51-F79C-4D82-8D43-2C0FCDE7D132
P2860
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@ast
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@en
type
label
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@ast
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@en
prefLabel
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@ast
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@en
P1433
P1476
Biochemical markers of bone tu ...... : potential uses and pitfalls.
@en
P2093
Patrick Garnero
Serge Cremers
P2860
P304
P356
10.2165/00003495-200666160-00001
P577
2006-01-01T00:00:00Z
P6179
1052932031